And given the environment you're talking about, will these new advisors get in the way of being able to get those kind of things to market. Yeah, this shouldn't come before acib. So this is a therapeutic. It's a long acting antiviral that Lenacapavir provides six months of protection against HIV and was extremely effective at preventing HIV infection in a high-risk population. that was high risk of contracting hiv. So it's a change in the formulation of an antiviral that allows it to be administered just twice a year and provides sustained exposure to the benefits of that antiviral. (07:32–07:43)
CLAIM
Asserts that Lenacapavir is effective in preventing HIV infection in high-risk populations.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
